title: Cytomegalovirus retinitis in advanced HIV-infected patients treated with protease inhibitors: incidence and outcome over 2 years.
abstract: We prospectively studied the incidence of cytomegalovirus (CMV) retinitis in 93 patients treated with highly active antiretroviral therapy (HAART) containing a protease inhibitor (PI), during a median follow-up period of 24 months. The median initial CD4+ count was 22 cells/microl (range, 1-311 cells/microl), and the median plasma HIV viral load was 5.1 log10 copies/ml (range, 2.4-6.4 log10 copies/ml). The fundus was examined monthly in patients with a history of CMV retinitis or an initial CD4+ count <50 cells/microl and every 3 months in the other patients. Of patients with previously controlled CMV retinitis, 1 of 7 relapsed. In addition, 6 of 59 patients with a CD4+ count <50 cells/microl and no history of CMV retinitis before starting PI therapy developed CMV retinitis. Of them, 3 had at least one relapse during follow-up. CD4+ counts were <40 cells/microl at the time of primary or recurrent CMV retinitis, except in two cases (147 cells/microl and 203 cells/microl). In conclusion, the incidence of CMV retinitis was 0.091 per patient-year among study subjects with advanced HIV infection who were receiving HAART (95% confidence interval [CI], 0.037-0.145). The time to progression of CMV retinitis (mean, 215 days; 95% CI, 113-317 days) was longer than reported before widespread use of PIs.
authors.affiliation: Department of Ophthalmology, Hôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France.
authors.forename: M
authors.initials: M
authors.lastname: Labetoulle
authors.forename: C
authors.initials: C
authors.lastname: Goujard
authors.forename: E
authors.initials: E
authors.lastname: Frau
authors.forename: H
authors.initials: H
authors.lastname: Rogier
authors.forename: F
authors.initials: F
authors.lastname: Niessen
authors.forename: V
authors.initials: V
authors.lastname: Furlan
authors.forename: O
authors.initials: O
authors.lastname: Lantz
authors.forename: D
authors.initials: D
authors.lastname: Lecointe
authors.forename: J F
authors.initials: JF
authors.lastname: Delfraissy
authors.forename: H
authors.initials: H
authors.lastname: Offret
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D000328:Adult; D018791:CD4 Lymphocyte Count; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D004359:Drug Therapy, Combination; D017245:Foscarnet / Q000008:administration & dosage / Q000627:therapeutic use; D015774:Ganciclovir / Q000008:administration & dosage / Q000627:therapeutic use; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence; D019469:Indinavir / Q000627:therapeutic use; D019888:Nelfinavir / Q000627:therapeutic use; D017063:Outcome Assessment, Health Care; D011446:Prospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D019438:Ritonavir / Q000627:therapeutic use; D019258:Saquinavir / Q000627:therapeutic use
chemical_list: D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D017245:Foscarnet; D019469:Indinavir; D019888:Nelfinavir; D019258:Saquinavir; D019438:Ritonavir; D015774:Ganciclovir